EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis

Zhuoran Sun, Yaru Tian, Shuangqing Lu, Jiling Niu, Qingfen Dong, Hui Zhu iD

Cancer Medicine · 2026-02 · 15 (2)

DOI: 10.1002/cam4.71607 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 08.02.2026. Verfasst von Zhuoran Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, …. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platinum‐based two‐agent chemotherapy combined with immunotherapy is now the first‐line standard of care for extensive‐stage small cell lung cancer (ES‐SCLC). Further studies are needed to determine whether continuing immunotherapy (IO) can provide benefit in patients whose disease has progressed after first‐line treatment. Therefore, we conducted a retrospective study to evaluate the efficacy of continuing IO in patients.

Methods

The study retrospectively collected clinical data of ES‐SCLC patients as progressive disease (PD) after receiving first‐line treatment with PD‐1/PD‐L1 inhibitors. According to whether to continue immunotherapy or not, patients were divided into the continuing IO group and the control group. The differences in progression‐free survival (PFS2, defined as time from progression on first‐line treatment to progression on second‐line treatment) and overall survival (OS) between the two groups were compared.

Result

As a result, a total of 489 patients from three cancer centers were enrolled in this study, of which 298 patients were included in the continuing IO group and 191 patients were included in the control group. By analysis, it was found that continuing IO could prolong OS (median: 18.82 months vs. 16.43 months, p = 0.008) and PFS2 (median: 4.13 months vs. 3.77 months, p = 0.04) compared to the control group. In subgroup analyses, continuing immunotherapy led to prolonged survival in patients with an initial efficacy evaluation of the complete response (CR) or partial response (PR). And there was also no difference in survival between the PD‐L1 inhibitor group and the PD‐1 inhibitor group in the comparison of different ICIs types.

Conclusions

Continuation of immunotherapy after standard first‐line immunotherapy plus chemotherapy can improve survival in patients with ES‐SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaImmunotherapyImmune Checkpoint InhibitorsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedDisease ProgressionNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

continuing immunotherapyextensive‐stage small‐cell lung cancer (ES‐SCLC)immune checkpoint inhibitors (ICIs)immunotherapy (IO)programmed death 1 (PD‐1) inhibitorprogrammed death ligand 1 (PD‐L1) inhibitor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
  • Shandong Yiyang Health Group Xinwen Central Hospital, Taian, China.

ORCID-Profile: Hui Zhu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Sun, Z., Tian, Y., Lu, S., Niu, J., Dong, Q., & Zhu, H. (2026). Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis. Cancer Medicine, 15(2). https://doi.org/10.1002/cam4.71607

Vancouver

Sun Z, Tian Y, Lu S, Niu J, Dong Q, Zhu H. Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis. Cancer Medicine. 2026;15(2). doi:10.1002/cam4.71607

BibTeX
@article{Sun2026,
  author = {Sun, Zhuoran and Tian, Yaru and Lu, Shuangqing and Niu, Jiling and Dong, Qingfen and Zhu, Hui},
  title = {Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.1002/cam4.71607}
}
Kostenlos starten →